Libara (Azelastine + Fluticasone) Nasal Spray

What Is Libara and What Is It Used For?

Libara belongs to a class of medicines that combine two different active substances to provide comprehensive relief from allergic rhinitis symptoms. Allergic rhinitis, commonly known as hay fever when triggered by seasonal allergens, affects an estimated 10–30% of the global adult population according to the World Health Organization (WHO). The condition is characterised by nasal congestion, sneezing, rhinorrhoea (runny nose), and nasal pruritus (itching), all of which significantly impair quality of life, sleep, and daily productivity.

The two active ingredients in Libara work through complementary mechanisms. Azelastine hydrochloride is a second-generation antihistamine that blocks H1 histamine receptors on the nasal mucosa. It also exhibits anti-inflammatory properties beyond simple histamine blockade, inhibiting the release of inflammatory mediators such as leukotrienes and platelet-activating factor (PAF). This dual action contributes to its rapid onset of effect, typically within 15 minutes of administration, making it one of the fastest-acting intranasal treatments available.

Fluticasone propionate is a potent synthetic corticosteroid with high topical anti-inflammatory activity and low systemic bioavailability. When applied to the nasal mucosa, it reduces inflammation by suppressing the release of cytokines, chemokines, and other pro-inflammatory mediators. It also decreases the influx of inflammatory cells, including eosinophils, mast cells, and T-lymphocytes, into the nasal tissue. The full anti-inflammatory benefit of fluticasone builds gradually over several days of regular use, with maximum efficacy typically achieved within one to two weeks.

Clinical studies have demonstrated that the combination of intranasal azelastine and fluticasone provides significantly greater symptom relief than either agent used alone. The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines recognise combination intranasal antihistamine/corticosteroid therapy as a preferred treatment option for patients with moderate to severe allergic rhinitis who do not respond adequately to monotherapy. This combination approach addresses both the immediate histamine-driven symptoms and the underlying chronic inflammatory process that characterises allergic rhinitis.

Libara is indicated for use in adults and adolescents aged 12 years and older. It is particularly suitable for patients who have previously tried intranasal corticosteroids or oral antihistamines alone without achieving satisfactory symptom control. The convenience of a single combination spray may also improve treatment adherence compared with using two separate nasal products.

What Should You Know Before Taking Libara?

Contraindications

Libara should not be used if you have a known hypersensitivity to azelastine hydrochloride, fluticasone propionate, or any of the excipients in the formulation. Patients with untreated localised infections of the nasal mucosa should not initiate treatment until the infection has been appropriately treated, as corticosteroids can impair local immune defences and potentially worsen infection.

If you have recently undergone nasal surgery or experienced nasal trauma, the use of intranasal corticosteroids should be delayed until healing has occurred. The corticosteroid component of Libara may impair wound healing in the nasal passages. Patients with active or quiescent tuberculosis of the respiratory tract should also exercise caution and use this product only under close medical supervision.

Individuals with severe hepatic impairment should use Libara with caution. Fluticasone propionate is extensively metabolised in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system, and impaired hepatic function may increase systemic exposure to the corticosteroid component, potentially raising the risk of systemic side effects.

Warnings and Precautions

Long-term use of intranasal corticosteroids may be associated with a risk of nasal septal perforation, although this is uncommon. Report any unusual nasal discomfort, persistent nosebleeds, or nasal crusting to your doctor. Regular monitoring of the nasal mucosa is advisable during prolonged treatment.

Corticosteroids can suppress the hypothalamic-pituitary-adrenal (HPA) axis, particularly when used at high doses or in combination with other corticosteroid-containing products (including inhaled, topical, or oral corticosteroids). If you are already receiving corticosteroid therapy for another condition, inform your prescriber, as the cumulative corticosteroid exposure may increase the risk of systemic effects such as adrenal suppression, growth retardation in adolescents, reduced bone mineral density, cataracts, and glaucoma.

Intranasal corticosteroids may cause a slight reduction in growth velocity in paediatric and adolescent patients. Healthcare providers should monitor growth regularly in adolescents receiving long-term treatment and weigh the benefits of treatment against potential growth effects. The ARIA guidelines recommend using the lowest effective dose to minimise systemic exposure.

Azelastine may cause drowsiness in some patients. If you experience sedation, avoid driving or operating machinery until you know how Libara affects you. Concurrent use of alcohol or other central nervous system (CNS) depressants may potentiate this effect.

Pregnancy and Breastfeeding

There is limited data on the use of the azelastine/fluticasone combination in pregnant women. Animal reproduction studies with corticosteroids have shown adverse effects at high systemic doses, including cleft palate and intrauterine growth restriction. However, intranasal fluticasone propionate has very low systemic bioavailability, and the risk with therapeutic nasal doses is considered low. Nevertheless, Libara should only be used during pregnancy if the expected benefit to the mother justifies the potential risk to the foetus.

It is not known whether azelastine is excreted in human breast milk. Fluticasone propionate is excreted in breast milk in small amounts at therapeutic doses. A decision should be made whether to discontinue breastfeeding or to discontinue treatment with Libara, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Consult your healthcare provider for personalised advice.

How Does Libara Interact with Other Drugs?

Drug interactions with Libara primarily involve the fluticasone propionate component, which is metabolised by the cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with potent CYP3A4 inhibitors can significantly increase the systemic exposure to fluticasone, potentially leading to corticosteroid-related adverse effects. The azelastine component has fewer clinically significant interactions, though its sedative properties may be additive with other CNS depressants.

It is important to provide your doctor or pharmacist with a complete list of all medications, supplements, and herbal products you are currently taking. Even seemingly harmless over-the-counter remedies and dietary supplements can occasionally interact with prescription medicines.

Major Interactions

Minor Interactions

What Is the Correct Dosage of Libara?

The dosage of Libara should be determined by your prescribing physician and tailored to the severity of your symptoms. Each actuation delivers 125 micrograms of azelastine hydrochloride and 50 micrograms of fluticasone propionate. The spray should be used consistently for optimal results, as the corticosteroid component requires regular administration to achieve its full anti-inflammatory effect.

Adults and Adolescents (12 Years and Older)

Treatment should be initiated at the start of the allergy season for seasonal allergic rhinitis, or used continuously for perennial allergic rhinitis. The duration of treatment should be limited to the period of allergen exposure for seasonal conditions. For perennial rhinitis, treatment may be continued for longer periods under medical supervision, with periodic reassessment of the need for continued therapy.

Children Under 12 Years

Elderly Patients

Missed Dose

If you forget to take a dose, use it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not use a double dose to make up for a forgotten one. Missing an occasional dose is unlikely to significantly affect your allergy control, but regular use is important for maintaining the anti-inflammatory benefit of the fluticasone component.

Overdose

Acute overdose with intranasal Libara is unlikely to cause serious problems. In the event of accidental ingestion or significant overdose, symptoms may include excessive drowsiness (from azelastine) and, with chronic overuse, potential adrenal suppression (from fluticasone). If you suspect an overdose, contact your local poison control centre or seek medical attention immediately. Treatment is supportive and symptomatic.

What Are the Side Effects of Libara?

Like all medicines, Libara can cause side effects, although not everybody gets them. The side effects listed below reflect the known safety profiles of both azelastine and fluticasone when used intranasally. Most side effects are localised to the nasal passages and are mild in severity. The combination product has a safety profile consistent with its individual components.

It is important to distinguish between common, expected side effects and those that warrant medical attention. Contact your doctor or pharmacist if any side effect becomes severe, persistent, or troublesome. Seek immediate medical attention if you experience signs of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat, difficulty breathing, or a severe rash.

The unpleasant taste (dysgeusia) reported with Libara is primarily attributable to the azelastine component. This occurs when the sprayed medication drips from the nasal passages to the back of the throat. Tilting the head slightly forward during administration and avoiding sniffing hard after spraying can help minimise this effect. Most patients find that the taste becomes less noticeable after the first few days of treatment.

Epistaxis (nosebleed) is one of the most commonly reported side effects of intranasal corticosteroids. It is usually mild and self-limiting. Directing the spray away from the nasal septum can help reduce the risk. If nosebleeds become frequent or severe, consult your doctor, as this may indicate nasal mucosal damage.

How Should You Store Libara?

Proper storage of Libara is important to ensure the medicine remains effective and safe throughout its shelf life. The nasal spray contains a suspension that must be shaken gently before each use to ensure uniform distribution of the active ingredients.

• Temperature: Store below 25°C (77°F). Do not refrigerate or freeze, as freezing may damage the spray mechanism and alter the suspension characteristics.
• Light: Keep in the original carton to protect from light. Exposure to direct sunlight or strong artificial light may degrade the active ingredients.
• Position: Store the bottle in an upright position with the dust cap on to prevent leakage and contamination.
• After first opening: Once opened, the nasal spray should typically be used within 6 months. Check the product label for specific instructions, as this may vary by manufacturer.
• Expiry date: Do not use Libara after the expiry date printed on the carton and bottle. The expiry date refers to the last day of that month.
• Children: Keep all medicines out of the sight and reach of children.

Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.

What Does Libara Contain?

Understanding the full composition of your medicine helps identify potential allergens and excipients that may affect tolerability. The active and inactive ingredients in Libara nasal spray are listed below.

Active Ingredients

• Azelastine hydrochloride: 125 micrograms per actuation – a second-generation antihistamine that blocks H1 receptors and exhibits additional anti-inflammatory properties.
• Fluticasone propionate: 50 micrograms per actuation – a potent synthetic corticosteroid with high topical activity and low systemic bioavailability.

Excipients (Inactive Ingredients)

The typical excipients found in combination azelastine/fluticasone nasal spray formulations include:

• Microcrystalline cellulose and carboxymethylcellulose sodium (suspending agents)
• Benzalkonium chloride (preservative)
• Edetate disodium (stabiliser)
• Polysorbate 80 (surfactant)
• Dextrose or glucose (tonicity agent)
• Phenylethyl alcohol (preservative)
• Hydrochloric acid and/or sodium hydroxide (pH adjustment)
• Purified water

The nasal spray is presented as a white to off-white homogeneous suspension in a high-density polyethylene (HDPE) or glass bottle fitted with a metered-dose spray pump. Each bottle typically provides 120 metered sprays. The spray pump delivers a consistent and reproducible dose with each actuation when used as directed.